The revenue explosion is low-quality (single large order with low margins) and the core business is losing money faster. With cash down to $2.66M and multiple capital-intensive projects underway, monitor for potential near-term equity or debt financing. The non-cash 'profit' is misleading — focus on the cash burn trajectory and asset/liability position.
Price Chart
Executive Summary
YD Bio reported financial results for the six months ended June 30, 2026, showing headline net income of $6.7M (vs a $1.9M loss in the prior period) and revenue up 315% to $0.85M. However, the net income was almost entirely driven by a $9.85M non-cash gain on warrant liabilities, and the core operating loss more than doubled to $3.2M; cash also dropped by over 55% to $2.66M.
Key Financial Metrics
Key Facts
- Revenue rose 315% YoY to ~$846,501, largely from a single large order for Fetroja ($327K) accounting for 39% of total revenue.
- Headline net income of $6.7M turned from a $1.9M loss, but was 100% dependent on a $9.85M non-cash fair value adjustment on warrant liabilities.
- Excluding the warrant liability gain, the underlying operational net loss widened 64% to ~$3.1M from ~$1.9M a year ago.
- Operating loss increased 66% to $3.23M as operating expenses outpaced gross profit growth.
- Cash and cash equivalents fell sharply by 56% to $2.66M from $6.01M at year-end 2025.
- No guidance or consensus estimates were provided; the stock's micro-cap profile amplifies volatility.
- The company is pursuing multiple capital-intensive initiatives (mergers, clinical trials, lab network expansion) against a rapidly shrinking cash base.
Financial Impact
Net income of $6.7M is entirely non-cash (warrant liability fair value); core cash-burn operations consumed $2.82M in 6 months; cash position fell to $2.66M.
Risk Factors
- Revenue concentration risk — one product (Fetroja) contributed 39% of 6-month revenue; loss of that customer would be materially disruptive.
- Cash runway risk — at the current operating cash burn rate (~$2.8M per 6 months), cash of $2.66M provides limited runway absent new financing.
- Dilution risk — the company has ~$4.5M in warrant liabilities; changes in fair value already swing reported earnings wildly.
- Business combination risk — pending merger/acquisition targets (EG BioMed, SSMC) require cash outlays and may not close as planned.
- Supplier concentration risk — over 60% of purchases from two suppliers; supply disruption could halt revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3353740 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 8w ago | Press Release | $3.78 $7.42 | ▼ −96.56% | ▼ −96.24% | $5.29 (−40.13%) |
Aug 11, 2026 10w ago | 6-K | $2.73 $3.93 | ▲ +43.77% | ▲ +44.83% | $5.29 (+93.77%) |
Apr 30, 2026 25w ago | Press Release | $4.80 $3.07 | ▲ +36.15% | ▲ +41.41% | $5.29 (−10.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers